These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 701660)

  • 1. Specific suppression of IgE antibodies. An immunotherapeutic goal achievable in the foreseeable future.
    Sehon AH
    J Allergy Clin Immunol; 1978 Nov; 62(5):257-60. PubMed ID: 701660
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose response of IgE and IgG antibodies during ragweed immunotherapy.
    Creticos PS; Van Metre TE; Mardiney MR; Rosenberg GL; Norman PS; Adkinson NF
    J Allergy Clin Immunol; 1984 Jan; 73(1 Pt 1):94-104. PubMed ID: 6607272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Induction of Antigen Specific and IgE selective suppression of antibody response (author's transl)].
    Matuhasi T; Usui M
    Rinsho Byori; 1980 Sep; 28(9):831-9. PubMed ID: 6166774
    [No Abstract]   [Full Text] [Related]  

  • 4. Hapten-specific IgE antibody responses in mice. IX. Suppression of IgE antibody production by passive transfer of T cells from adjuvant-primed syngeneic mice.
    Chiorazzi N; Tung AS; Katz DH
    J Immunol; 1979 Apr; 122(4):1495-501. PubMed ID: 312844
    [No Abstract]   [Full Text] [Related]  

  • 5. [The environment and the immune system].
    Baenkler HW
    Dtsch Med Wochenschr; 1985 Feb; 110(8):312-5. PubMed ID: 3971883
    [No Abstract]   [Full Text] [Related]  

  • 6. Suppression of reaginic antibody (IgE) formation in mice by treatment with anti-mu antiserum.
    Manning DD; Manning JK; Reed ND
    J Exp Med; 1976 Jul; 144(1):288-92. PubMed ID: 819612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of IgE antibody production by suppressor substances.
    Katz DH
    J Allergy Clin Immunol; 1978 Jul; 62(1):44-55. PubMed ID: 307012
    [No Abstract]   [Full Text] [Related]  

  • 8. IgE isotype suppression in anti-epsilon-treated mice.
    Bozelka BE; McCants ML; Salvaggio JE; Lehrer SB
    Immunology; 1982 Jul; 46(3):527-32. PubMed ID: 6807838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy.
    Ganglberger E; Barbara Sponer ; Schöll I; Wiedermann U; Baumann S; Hafner C; Breiteneder H; Suter M; Boltz-Nitulescu G; Scheiner O; Jensen-Jarolim E
    FASEB J; 2001 Nov; 15(13):2524-6. PubMed ID: 11641259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosensor-based characterization of serum antibodies during development of an anti-IgE immunotherapeutic against allergy and asthma.
    Pol E; Karlsson R; Roos H; Jansson A; Xu B; Larsson A; Jarhede T; Franklin G; Fuentes A; Persson S
    J Mol Recognit; 2007; 20(1):22-31. PubMed ID: 17036306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between antigen and antibody-induced suppression of IgE antibody formation in the rat.
    Opree W
    Acta Allergol; 1976 Aug; 31(4):321-36. PubMed ID: 989674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seasonal changes in IgE antibodies and their relationship to IgG antibodies during immunotherapy for ragweed hay fever.
    Yunginger JW; Gleich GJ
    J Clin Invest; 1973 May; 52(5):1268-75. PubMed ID: 4735589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy.
    Wachholz PA; Soni NK; Till SJ; Durham SR
    J Allergy Clin Immunol; 2003 Nov; 112(5):915-22. PubMed ID: 14610480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renaissance of the blocking antibody concept in type I allergy.
    Flicker S; Valenta R
    Int Arch Allergy Immunol; 2003 Sep; 132(1):13-24. PubMed ID: 14555854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the IgE antibody response.
    Ishizaka K
    Int Arch Allergy Appl Immunol; 1981; 66 Suppl 1():1-7. PubMed ID: 6975757
    [No Abstract]   [Full Text] [Related]  

  • 17. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy.
    Kussebi F; Karamloo F; Rhyner C; Schmid-Grendelmeier P; Salagianni M; Mannhart C; Akdis M; Soldatova L; Markovic-Housley Z; Von Beust BR; Kündig T; Kemeny DM; Blaser K; Crameri R; Akdis CA
    J Allergy Clin Immunol; 2005 Feb; 115(2):323-9. PubMed ID: 15696088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgE regulation during immunotherapy of allergic diseases.
    Perelmutter L
    Ann Allergy; 1986 Aug; 57(2):78-85. PubMed ID: 2943197
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and suppression of IgE antibodies.
    Greenberger PA
    Allergy Proc; 1993; 14(1):61-2. PubMed ID: 7681802
    [No Abstract]   [Full Text] [Related]  

  • 20. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
    McMenamin C; Holt PG
    J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.